Depreciation of Emergent BioSolutions Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Emergent BioSolutions Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Emergent BioSolutions Inc. Depreciation for the quarter ending 31 Dec 2025 was $7,200,000, a 26% decline year-over-year.
  • Emergent BioSolutions Inc. Depreciation for the twelve months ending 31 Dec 2025 was $30,700,000, a 30% decline year-over-year.
  • Emergent BioSolutions Inc. annual Depreciation for 2025 was $30,700,000, a 30% decline from 2024.
  • Emergent BioSolutions Inc. annual Depreciation for 2024 was $43,700,000, a 27% decline from 2023.
  • Emergent BioSolutions Inc. annual Depreciation for 2023 was $59,500,000, a 29% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Emergent BioSolutions Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $30,700,000 $7,200,000 -$2,500,000 -26% 01 Oct 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q3 2025 $33,200,000 $7,100,000 -$3,000,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $36,200,000 $7,300,000 -$4,900,000 -40% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $41,100,000 $9,100,000 -$2,600,000 -22% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $43,700,000 $9,700,000 -$3,700,000 -28% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 $47,400,000 $10,100,000 -$1,600,000 -14% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $49,000,000 $12,200,000 -$4,600,000 -27% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $53,600,000 $11,700,000 -$5,900,000 -34% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $59,500,000 $13,400,000 -$4,600,000 -26% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
Q3 2023 $64,100,000 $11,700,000 -$8,600,000 -42% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $72,700,000 $16,800,000 -$11,700,000 -41% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $84,400,000 $17,600,000 +$1,000,000 +6% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $83,400,000 $18,000,000 +$2,300,000 +15% 01 Oct 2022 31 Dec 2022 10-K 04 Mar 2025 2024 FY
Q3 2022 $81,100,000 $20,300,000 +$5,900,000 +41% 01 Jul 2022 30 Sep 2022 10-Q 11 Dec 2023 2023 Q3
Q2 2022 $75,200,000 $28,500,000 +$10,000,000 +54% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $65,200,000 $16,600,000 +$3,000,000 +22% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $62,200,000 $15,700,000 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2024 2023 FY
Q3 2021 $14,400,000 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $18,500,000 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $13,600,000 01 Jan 2021 31 Mar 2021 10-Q 29 Apr 2022 2022 Q1

Emergent BioSolutions Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $30,700,000 -$13,000,000 -30% 01 Jan 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
2024 $43,700,000 -$15,800,000 -27% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
2023 $59,500,000 -$23,900,000 -29% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
2022 $83,400,000 +$21,200,000 +34% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2025 2024 FY
2021 $62,200,000 +$12,100,000 +24% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2024 2023 FY
2020 $50,100,000 +$600,000 +1.2% 01 Jan 2020 31 Dec 2020 10-K/A 11 Dec 2023 2022 FY
2019 $49,500,000 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.